The way Washington, DC, works will make it difficult to enact any meaningful change that will cause a difference in how much patients pay for prescription drugs, said Joe Antos, PhD, the Wilson H. Taylor Resident Scholar in Health Care and Retirement Policy at the American Enterprise Institute.
The way Washington, DC, works will make it difficult to enact any meaningful change that will cause a difference in how much patients pay for prescription drugs, said Joe Antos, PhD, the Wilson H. Taylor Resident Scholar in Health Care and Retirement Policy at the American Enterprise Institute.
Transcript
How well do you think Congress and the Trump administration are pursuing policies to curb the cost of prescription drugs?
Prescription drug prices and costs are the same thing for most people. This is a huge issue in Washington, DC. It’s equally a huge issue at the pharmacy counter for the average person. Especially older people who tend to need more prescription drugs. It’s a big, big issue.
I think, as usual, Washington kind of has it wrong. What matters to the average patient is not what the overall price is, not what the list price is, it has nothing to do with the strange machinations of PBMs [pharmacy benefit managers] or drug companies or retail pharmacies. It has to do with when you go to the pharmacist and you pull out your credit card, how much do they want out of you? That’s the issue.
And I don’t think that Washington politics operates on that level that the average consumer would detect anything. For example, the administration, and also Congress, has been talking about somehow getting the rebates that are in the system behind the scenes to the patient when he or she picks up the prescription. The problem with that is: A) it’s impossible to know what that amount is; B) the likely amount per prescription is a very, very small number; C) from a political standpoint, and this is all that really matters, the average patient doesn’t know what they were going to pay in the first place. So, when you say you got $2 off: A) big deal; B) $2 off of what?
So, I think as a political move, there’s nothing there. As a move in terms of trying to get what people call greater transparency in pricing, it also kind of misses the point. Because the issue is not rebates, per say, but what the flow of funds are and who gets to keep the money among the many, many intermediaries between the drug manufacturer and the patient. There are a lot of people involved, everybody gets their cut. Where does the money go? Is there accountability? The answer is we don’t know.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More